Pharmacokinetics of enrofloxacin given by the oral, intravenous and intramuscular routes in broiler chickens

Canadian Journal of Veterinary Research

Volumn 63, Issue 3, 1999, Pages 193-200

  Bugyei, Kwasi ^a,b   Black, W D ^a   McEwen, Scott ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b UNIVERSITY OF GHANA   (Ghana)

Author keywords

[No Author keywords available]

Indexed keywords

ENROFLOXACIN; PLASMA PROTEIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHICKEN; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; MEAN RESIDENCE TIME; MODEL; NONHUMAN;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFECTIVE AGENTS; BIOLOGICAL AVAILABILITY; CHICKENS; FLUOROQUINOLONES; HALF-LIFE; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAMUSCULAR; QUINOLONES;

EID: 0033503653     PISSN: 08309000     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. LESHER GY, FROELJCH EJ, GRUETT MD, BAILEY JA, BRUNDAGE RP. 1.8-naphthyridine derivatives: A new class of chemotherapeutic agents. J Med Pharm Chem 1962; 5: 1063-1065.
2. GOODMAN LS, GILMAN A. The Pharmacological Basis of Therapeutics. 7th ed. New York: Macmillan. 1985: 1057-1060.
3. MONTAY G, GOUEFFON Y, ROQUET F. Absorption, distribution, metabolic fate and elimination of perfloxacin mesylate in mice, rats, dogs, monkeys and humans. Antimicrob Agents Chemother 1984; 25: 463-472.
4. BAUDITZ R. Results of clinical studies with Baytril™ in poultry Vet Med Rev 1987a; 2: 130-136.
5. BAUDITZ R. Results of clinical studies with Baytril™ in calves and pigs. Vet Med Rev 1987b; 2: 122-129.
6. rial agents: A new class of antimicrobial agents for use in veterinary medicine. Proc West Vet Conf, Las Vegas, Nevada. Shawnee: Mobay Corp., 1988: 5-16.
7. FEIERL G, PSCHAID A, SIXL B, MARTH E. Increase in ciprofloxacin resistance in Campylobacter species in Styria. Austria. Int J Med Microbiol Virol Parasitol Infect Dis 1994; 218: 471-474.
8. GRIGGS DJ, HALL MC, JIN YF, PIDDOCK LJ. Quinolone resistance in veterinary isolates of Salmonella. J Antimicrob Chemother 1994; 33: 1173-1189.
9. BERG J. Clinical indications for enrofloxacin in domestic animals and poultry. In: Quinolones: A new class of antimicrobial agents in veterinary medicine. Proc West Vet Conf, Las Vegas, Nevada. Shawnee: Mobay Corp., 1988: 5-16.
10. SHEER M. Studies on the antimicrobial activity of Baytril™. Vet Med Rev 1987b; 2: 90-99.
11. VANCUTSEM PM, BABISH JG, SCHWARK WS. The fluoroquinolone antimicrobials: Structure, antimicrobial activity, pharmacokinetics, clinical use in domestic animals and toxicity. Cornell Vet 1990; 80: 173-186.
12. GREENE CE, BUDSBERG SC. Veterinary use of quinolones. In: Hooper DC, Wolfson JS, eds. Quinolone Antimicrobial Agents. Washington, DC: Am Soc Microbiol, 1993: 473-488.
13. ARRET B, JOHNSON DP, KIRSHBAUM A. Outline of details for microbiological assays of antibiotics: Second Revision. Drug Standards. J Pharm Sci 1971; 60: 1689-1694.
14. STEELE R, TORRIE J. Principles and Procedures of Statistics: A Biometrical Approach. 2nd ed. Toronto: McGraw-Hill Book Co, 1980: 137-284.
15. GIBALDI M, PERRIER D. Pharmacokinetics, vol I. New York: Marcel Dekker Inc. 1975: 45-95.
16. BAGGOT JD. Principles of Drug Disposition in Domestic Animals: The Basis of Veterinary Clinical Pharmacology. Toronto: WB Saunders. 1977: 1-238.
17. YAMAOKA K, NAKAGAWA T, UNO T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokin Biopharmaceut 1978; 6. 165-175.
18. NOTARI RE. Biopharmaceutic and Clinical Pharmacokinetics. An Introduction. 4th ed. New York: Marcel Dekker, 1987: 106-129.
19. . ROWLAND M, TOZER TN. Clinical Pharmacology: Concepts and Applications. 2nd ed. Philadelphia: Lea & Febiger, 1989: 479-483
20. KUNIN CM, DORNBUSH AC, FINLAND M. Distribution and excretion of four tetracycline analogues in normal young men. J Clin Invest, 1959; 38: 1950-1963.
21. BAGGOT JD, DAVIS LE. Plasma protein binding of digitoxin and digoxin in several mammalian species. Res Vet Sci 1973; 15: 81-87.
22. PURCELL W, BASS G, CLAYTON J. Strategy of drug design: A guide to biological activity. Toronto: Willey Interscience Publ, 1973: 126-143.
23. ANADON A, MARTINEZ-LARRANAGA MR, DIAZ MJ, BRINGAS P. Pharmacokinetics and residues of enrofloxacin in chickens. Am J Vet Res 1995; 56: 501-506.
24. ANADON A, MARTINEZ-LARRANAGA MR, VELEZ C, DIAZ MJ, BRINGAS P. Pharmacokinetics of norfloxacin and norfloxacin and its N-desethyl- and Oxometabolites in broiler chickens. Am J Vet Res 1992; 53: 2084-2089.
25. DOWLING PM, WILSON RC, TYLER JW, DURAN SH. Pharmacokinetics of ciprofloxacin in ponies. J Vet Pharmacol Therap 1995; 18: 7-12.
26. FAO/WHO JOINT EXPERT COMMITTEE ON FOOD ADDITIVES. Toxicological evaluation of certain veterinary drug residues in food. Geneva. WHO Food Additives Series. 27th Int Prog Chem Safety/WHO, 1991: 1-62.
27. ATTA A, SHARIF L. Pharmacokinetics of ciprofloxacin following intravenous and oral administration in broiler chickens. J Vet Pharmacol Therap 1997; 20. 326-329.
28. FLAMMER K, AUCOIN DP, WHITT DA. Intramuscular and oral disposition of enrofloxacin in African grey parrots following single and multiple doses. J Vet Pharmacol Therap 1991; 14: 359-366.
29. DORRESTEIN GM, VERBURG E. Pharmacokinetics of enrofloxacin in homing pigeons. Simon F, Lees P, Semjen G, eds. Proc 4th Cong Euro Assoc Vet Pharmacol Toxicol. 1990: Budapest. Vet Sci 1990: 27-30.
30. CONZELMAN GM, BABISH JG, DAVIDSON JN, MCMILLAN RA, COPELAND DD. Pharmacokinetics of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo7-(4-ethyl-1-piperazyl)-3- quinolonecarboxylic acid (Bay Vp 2674) in chicks. Proc West Pharmacol Soc 1987; 30. 393-395.
31. GILES CJ, MAGNONIGLE RA, GRIMSHAW WTR. Clinical pharmacokinetics and parenterally administered danofloxacin in cattle. J Vet Pharmacol Therap 1991; 14: 400-410.
32. SCHOSBERG A, ERSHOV E, BELLAICHE M, HANJI V, WEISMAN Y. The effects of enrofloxacin on hepatic microsomal mixed function oxidases in broiler chicken. J Vet Pharmacol Therap 1995; 4: 311-313.
33. SHEER M. Concentration of active ingredients in serum and in tissues after oral and parenteral administration of Baytril™. Vet Med Rev 1987; 2: 104-118.
34. DUVAL J, BUDSBERG S. Cortical bone concentrations of enrofloxacin in dogs. Am J Vet Res 1995; 56: 188-192.
35. STEFFENAK I, HORAMAZABAL V, YNDESTAD M. Reservoir of quinolone residues in fish. Food Addtt Contam 1991; 8: 777-780.
36. TAKACS-NOVAK K, NORSZAL B, HERMECZ I, KERESZTURI G, PODANYI B, SZASZ G. Protonation equilibria of quinolone antibacterials. J Pharm Sci 1990; 79: 1023-1028.
37. CABANES A, ARBOIX M, ANTON JMG, REIG F. Pharmacokinetics of enrofloxacin after intravenous and intramuscular injection in rabbits. Am J Vet Res 1992; 53: 2090-2093.
38. KAARTENIN L, SALONEN M, ALLI L, PYORALA S. Pharmacokinetics of enrofloxacin after single intravenous, intramuscular and subcutaneous injections in lactating cows. J Vet Pharmacol Therap 1995; 5: 357-362.
39. KARABALUT N, DRUSANO GL. Pharmacokinetics of the quinolone antimicrobial agents. In: Crumplin GC, ed. The 4-quinolone antimicrobial agents in vitro. New York: Springer-Verlag. 1993: 195-223.
40. JOOS B, LEDERGERBER B, FLEPP M, BETTEX JD, LUTHY R, SIEGENTHALER W. Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine. Antimicrob Agents Chemother 1985; 27: 353-356.